Ophthalmogenetics and Gene Therapy

Ophthalmic hereditary qualities are worried about the hereditary commitment to ophthalmic illness, including assurance of examples and dangers of legacy, and in addition finding, visualization, and advancement of medications for hereditary variations from the norm. The advances in gene therapy maintain extensive promise for the cure of ophthalmic conditions. Gene therapy is additionally in a position to deal with primary open-angle glaucoma (POAG) in animal models, and research show it is economically viable. Genes may additionally be delivered into cells in vitro or in vivo making use of viral or non-viral vectors. Recent technical advances have led to the demonstration of the molecular basis of a range of ocular diseases.

  • Genetics of Myopia Development
  • Gene Therapy
  • Usher syndrome
  • Familial exudative vitreal retinopathy
  • Retinoblastoma
  • Leber hereditary optic neuropathy (LHON)
  • Optic atrophy
  • Genetics of Myopia Development

Related Conference of Ophthalmogenetics and Gene Therapy

March 18-19, 2024

5th World Congress on Ophthalmology and Vision Science

Zurich, Switzerland
April 25-26, 2024

24th Global Ophthalmologists Annual Meeting

London, UK
May 09-10, 2024

7th International Eye and Vision Congress

Barcelona, Spain
May 16-17, 2024

8th World Congress on Eye and Vision

Rome, Italy
June 13-14, 2024

9th International Conference on Eye and Vision

Barcelona, Spain
October 10-11, 2024

34th World Congress on Ophthalmology and Optometry

Madrid, Spain
October 10-11, 2024

10th Global Ophthalmology Meeting

Madrid, Spain

Ophthalmogenetics and Gene Therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in